Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19

Frontiers in Immunology

Immunology

Steven Rubin¹  Philip R. Krause²  Marion F. Gruber³ 

[1]GlaxoSmithKline (GSk), Rockville, MD, United States

[2]Independent Consultant, Bethesda, MD, United States

[3]International AIDS Vaccine Initiative, New York, NY, United States

关键词: filovirus;    Ebola;    Marburg;    Sudan;    vaccine;    effectiveness;    correlates of protection;    immunobridging;   

DOI  :  10.3389/fimmu.2023.1109486

 received in 2022-11-27, accepted in 2023-01-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV) and Marburg virus (MARV), are members of the Filoviridae family that can cause severe disease and death in humans and animals. The reemergence of Ebola, Sudan and Marburg virus disease highlight the need for continued availability of safe and effectives vaccines as well as development of new vaccines. While randomized controlled trials using disease endpoints provide the most robust assessment of vaccine effectiveness, challenges to this approach include the unpredictable size, location, occurrence and duration of filovirus disease outbreaks. Thus, other approaches to demonstrating vaccine effectiveness have been considered. These approaches are discussed using examples of preventive vaccines against other infectious diseases. In addition, this article proposes a clinical immunobridging strategy using licensed EBOV vaccines as comparators for demonstrating the effectiveness of filovirus vaccine candidates that are based on the same licensed vaccine platform technology.

【 授权许可】

Unknown   
Copyright © 2023 Gruber, Rubin and Krause